Alemtuzumab (anti-CD52; Campath-1H) is effective in fludarabine-refractory chronic lymphocytic leukemia (CLL), but is associated with infection and early onset neutropenia. To reduce toxicity, filgrastim (G-CSF) was administered concurrently with alemtuzumab. In total, 14 CLL patients (median age 59) with a median of 3.5 prior regimens (range 1-12) received i.v. alemtuzumab, stepped up from 3 to 30 mg the first week, then 30 mg thrice weekly for 12 weeks. Filgrastim 5 lg/kg was administered daily 5 days before and throughout alemtuzumab therapy. Six patients developed cytomegalovirus (CMV) reactivation 3-6 weeks into treatment; six patients developed fever, three neutropenia, and one pneumonia. The patient with CMV pneumonia died; ganciclovir cleared CMV in the other patients. Five patients developed early neutropenia (weeks 2-5). Four patients developed delayed neutropenia (weeks 10-13) unassociated with CMV reactivation. Nine patients ceased therapy because of infectious and hematologic toxicity. Five partial responses were noted, all in patients with lymph nodes 45 cm, lasting a median of 6.5 months (range 5-13). Filgrastim and alemtuzumab were given concurrently with manageable infusion toxicity and clinical activity, but the efficacy of this regimen was limited by delayed neutropenia of unclear etiology and CMV reactivation. Filgrastrim should not be administered prophylactically during alemtuzumab therapy outside clinical trials.
Introduction
Alemtuzumab (Campath-1H), a humanized anti-CD52 antibody, 1,2 is active in fludarabine-refractory chronic lymphocytic leukemia (CLL), with a 33% response rate in a large pivotal trial that gained FDA marketing approval. While such patients are predisposed to infections even in the absence of treatment, infections occurred in 55% of patients (27% grade [3] [4] in the pivotal study, and 13% developed septicemia. 3 Such infections are likely secondary to underlying disease, profound cellular immune suppression, and early neutropenia associated with alemtuzumab therapy. 2 In an attempt to decrease alemtuzumabinduced neutropenia and potentially enhance neutrophil antibody dependent cellular cytotoxicity, we performed a phase I/II study of combined granulocyte-colony stimulating factor (G-CSF; Filgrastim) and alemtuzumab in relapsed and refractory CLL.
Materials and methods
Patients with relapsed CLL were enrolled and provided written consent to participate in this institutional review boardapproved protocol. Filgrastim 5 mg/kg was administered subcutaneously daily 5 days before and continuously through the 12-week alemtuzumab treatment period. Alemtuzumab was administered identically to the CAM211 study and used similar prophylaxis for pneumocystis carinii pneumonia and varicella zoster that continued for 6 months post-therapy. 3 The alemtuzumab dose was stepped up from 3 to 30 mg during the first week, and then given 30 mg thrice weekly for 12 weeks. Blood counts were monitored weekly. Cytomegalovirus (CMV) was monitored weekly with a semiquantitative DNA hybrid capture assay. 4 Interphase cytogenetics were performed as previously published. 5 CLL response was assessed by NCI 96 criteria. 6 Toxicity was graded according to NCI Common Toxicity criteria.
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Results

Patient demographics
In total, 14 patients with a median age of 59 years (range 47-74) were enrolled. In total, 10 patients were male (71%), 11 had bulky lymph node enlargement 45 cm (79%), and eight were Rai stage III/IV (57%). Prior therapy included a median of 3.5 regimens (range 1-12), with 13 patients (93%) refractory to fludarabine. Five patients had del(17)(p13.1). These features are summarized in Table 1 .
Nonhematologic toxicity
Filgrastim was well tolerated. Alemtuzumab infusion toxicity was manageable; all patients received full dose alemtuzumab within 1 week of starting therapy. While all patients experienced grade 1-2 infusion toxicity, no patient experienced grade 3-5 infusion toxicity, and all infusion toxicity resolved within 24 h. However, two patients experienced severe, grade 3 fatigue, and both patients were removed from study by week 5 due to disease progression or infection. Rapid decrease in blood CLL cells concurrent with increased LDH was noted in a subset of patients with the initial three doses of alemtuzumab. While no patient developed overt tumor lysis syndrome, one patient developed grade 4 hyperuricemia. Grade 3 laboratory abnormalities included hypophosphatemia (4), elevation in alkaline phosphatase (3), hyperglycemia (2), hyperkalemia (1), hypokalemia (1), and hyponatremia (1); all laboratory abnormalities were transient. These toxicities are summarized in Table 2 .
Infectious toxicity
Two patients were hospitalized for neutropenic fever; CMV was not implicated in either patient. One of these two patients died of fusarium and polymicrobial sepsis; no organism was isolated in the other patient. Six patients (43%) developed CMV reactivation between weeks 3 and 6 that heralded symptomatic CMV disease (six fever, three neutropenia, one pneumonia) requiring ganciclovir therapy. The patient with CMV pneumonia developed fever and cough during week 4 of treatment. He was admitted for empiric antibiotic coverage, and his CMV hybrid capture assay was positive at a ratio of 1.69. Of note, his CMV hybrid capture assay the previous week had been negative. Bronchoscopy and bronchoalveolar lavage confirmed the diagnosis of CMV pneumonia. Despite treatment with CMV immune globulin, ganciclovir and foscarnet, his pulmonary status progressively declined, and he died of respiratory arrest 4 weeks after his initial hospital admission. Ganciclovir reduced CMV viral load to undetectable levels in the other five patients. Infectious toxicity is summarized in Tables 2 and 3 .
Hematologic toxicity
Nine patients experienced neutropenia (ANC o1000); a biphasic pattern was observed with both early (five patients; weeks 2, 2, 4, 4, 5) and delayed (four patients; weeks 10, 10, 13, 13) onset (Table 3) . Figures 1 and 2 depict ANC over time in patients who developed early ( Figure 1 ) and late neutropenia ( Figure 2 ), respectively (Patient 9 experienced neutropenia of only 1 week's duration and is therefore not depicted in Figure 1 ). Two of the five patients who developed early neutropenia did not recover ANC X1000 and died of infection; the other three recovered ANC X1000 1, 2 and 5 weeks after onset of neutropenia. Four patients with early neutropenia were evaluated with bone marrow biopsy. Two were evaluated at the time of neutropenia; both were hypocellular, and persistent CLL was noted in one of these two patients. The other two with early neutropenia were evaluated following recovery of ANC; both were hypocellular with persistent CLL. Delayed neutropenia in four patients occurred in the absence of CMV and was not responsive to increased doses of filgrastim; patients recovered ANC X1000 within 3-5 weeks with cessation of alemtuzumab ( Table 3 ). All four patients had hypocellular marrows at the time of neutropenia without evidence of disease. Two patients in the delayed neutropenia group had subsequent marrow evaluation demonstrating recovery of normal cellularity within 2 months of ending alemtuzumab. The etiology of the delayed neutropenia was unclear.
In total, 11 patients developed grade 3 anemia, for which they received packed red blood cell transfusions; the remaining three patients experienced no decline in hemoglobin from baseline. Two patients were not evaluable for platelet toxicity due to a baseline platelet count less than 20 000/ml. Of 12 evaluable patients, 11 developed grade 3 (n ¼ 5) or grade 4 (n ¼ 6) thrombocytopenia, and patients received platelet support as needed. Hematologic toxicity is summarized in Table 2 .
Response
Patients received a median of 5.5 weeks (range 2.5-12) of alemtuzumab (Table 1) . Four patients completed therapy. Nine patients ceased therapy because of CMV disease or neutropenia, and one patient refused further treatment. Five patients (36%), all of whom had lymph nodes 45 cm, attained a partial response (PR), including two with del(17)(p13.1). Of the four patients who completed the full 12 weeks of therapy, three attained a PR, vs only two of the 10 patients who did not complete treatment due to toxicity. Responses lasted a median of 6.5 months (range 5-13). Data are summarized in Table 1 .
Discussion
Our results demonstrate that filgrastim and alemtuzumab can be administered concurrently with manageable infusion toxicity Although the initial design of this study was to diminish infectious morbidity and early onset neutropenia, neither goal was obtained. While only two of 14 patients developed grade 4-5 non-CMV infectious toxicity, six patients reactivated CMV. Ganciclovir successfully cleared CMV viral load in five of six patients. However, one patient died of CMV pneumonia despite weekly CMV monitoring and aggressive therapy with CMV immune globulin, ganciclovir and foscarnet. Additionally, most patients who recovered from CMV infection suffered disease progression before alemtuzumab could be restarted. Myelosuppression due to ganciclovir also hampered the reinstitution of alemtuzumab in these patients. Thus, CMV disease severely limited the clinical efficacy of this regimen. Interestingly, CMV reactivation did not correlate with a higher number of prior chemotherapies. The median number of prior regimens was 2 (range 1-6) for the six patients who reactivated CMV, compared to four (range 2-12) for the eight patients who remained CMV negative. Four patients, who had received 2-4 prior regimens, completed 12 weeks of alemtuzumab therapy without reactivation of CMV. Interpretation of these findings is limited by the fact that patients' CMV serology was not evaluated prior to initiation of treatment; therefore, it is not clear which patients were at increased risk due to previous CMV exposure. However, the lack of correlation with prior therapy illustrates the profound immunosuppressive effects of alemtuzumab, and demonstrates the need to vigilantly watch for early CMV reactivation in all patients receiving alemtuzumab.
Neutropenia was also problematic in this study, with five patients developing early neutropenia and four other patients developing delayed neutropenia 10-13 weeks after initiation of therapy. The 38% frequency of neutropenia observed within the first 5 weeks of therapy is similar to the 30% observed in the pivotal CAM211 study. 3 While filgrastim was not planned in the CAM211 study, 18% of patients in that study received filgrastim or GM-CSF while receiving alemtuzumab. Unfortunately, the CAM211 study did not assess the efficacy of growth factor in diminishing neutropenia, and no other study has reported the concurrent use of filgrastim and alemtuzumab. Our data do not indicate that filgrastim can diminish early neutropenia or infections induced by alemtuzumab therapy. We also noted Absolute neutrophil count vs time (weeks) in four patients developing delayed onset neutropenia.
Filgrastim and alemtuzumab and CML TS Lin et al delayed neutropenia that, to our knowledge, has not been previously described as a complication of alemtuzumab. Delayed neutropenia occurred in four of six patients (67%) who received nine or more weeks of therapy and was not associated with CMV or persistent CLL. Only one patient developed fever during the period of neutropenia. The neutropenia was self-limited, with patients recovering ANC X1000 within 2 months of discontinuing alemtuzumab.
The etiology of this delayed neutropenia is unclear. One possible explanation is that patients suffered from bone marrow exhaustion from prior therapy, and filgrastim only delayed the inevitable hematologic toxicity of alemtuzumab. Interestingly, patients experienced a wide range of responses to initiation of filgrastim, with a few patients experiencing dramatic rises in ANC with modest increases in ANC in most patients. However, there was no correlation with number of prior therapies and development of early or delayed onset neutropenia. While all patients with delayed neutropenia recovered within 5 weeks, two patients with early onset neutropenia did not recover their neutrophil count and died of infection. While there is no evidence that prophylactic filgrastim 'masked' the development of neutropenia or resulted in delayed neutrophil recovery in these two patients, the use of prophylactic filgrastim during alemtuzumab therapy should not be pursued outside clinical trials.
Conclusion
The results of this study suggest a limited role for filgrastim in preventing early neutropenia or infections associated with alemtuzumab. However, the promising results in eliminating bulky lymph nodal disease in patients with del(17)(p13.1), who constitute the worst prognostic group in CLL, provide justification for continued pursuit of this combination. The etiology of the delayed onset neutropenia observed in our study remains unknown, and it is unclear whether the use of continuous daily filgrastim was responsible for this previously undescribed toxicity with alemtuzumab therapy. Until the significance and etiology of this delayed neutropenia are understood, prophylactic filgrastrim should not be administered with alemtuzumab outside clinical trials. CMV reactivation restricted the clinical efficacy of this regimen but, surprisingly, was not associated with heavy pretreatment. The use of CMV serology to identify patients who have previously been exposed to CMV and are at highest risk of CMV viremia should be considered to guide judicious use of this regimen in future studies.
